Prognostic factors in desmoid tumours: an example of translational oncology Soledad Gallego Melcón Editorial 08 April 2011 Pages: 139 - 140
Mechanism of hot flashes Santiago Vilar-GonzálezAlberto Pérez-RozosRuben Cabanillas-Farpón Educational Series 08 April 2011 Pages: 143 - 147
Direct antitumour activity of zoledronic acid: preclinical and clinical data Joaquim Bosch-BarreraSofía D. MerajverCatherine Van Poznak Educational Series 08 April 2011 Pages: 148 - 155
New technologies in cancer. Protein microarrays for biomarker discovery Sergio MatarrazMaría González-GonzálezManuel Fuentes Educational Series 08 April 2011 Pages: 156 - 161
Treatment recommendations for metastatic colorectal cancer Enrique ArandaAlbert AbadEduardo Díaz-Rubio Educational Series 08 April 2011 Pages: 162 - 178
Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer Cristina GrávalosCarlos Gómez-MartínAntonio Jimeno Research Articles 08 April 2011 Pages: 179 - 184
Spinal cord astrocytoma: multidisciplinary experience M. Isabel Tovar MartínEscarlata López RamírezMercedes Zurita Herrera Research Articles 08 April 2011 Pages: 185 - 188
Multimodal treatment of desmoid tumours: the significance of local control Bella PajaresEsperanza TorresEmilio Alba Research Articles 08 April 2011 Pages: 189 - 193
Alternate PAX3 and PAX7 C-terminal isoforms in myogenic differentiation and sarcomagenesis Elizabeth CharytonowiczIgor MatushanskyMel Ziman Research Articles 08 April 2011 Pages: 194 - 203
Circulating tumour cells in peripheral blood: potential impact on breast cancer outcome María José SerranoJosé Antonio LorentePedro Sánchez Rovira Research Articles 08 April 2011 Pages: 204 - 208
Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error? Carmen BalañáOlatz EtxanizAlex Martínez Correspondence 08 April 2011 Pages: 209 - 210